Black Diamond Therapeutics, Inc.
BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The cā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.69
Price-1.46%
-$0.03
1Y
Price
Market Cap
$96.840m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow Margin-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-
1y CAGR-
3y CAGR-
5y CAGREarnings
-$43.211m
+130.9%
1y CAGR+52.0%
3y CAGR+45.8%
5y CAGREPS
-$0.76
+128.4%
1y CAGR+62.1%
3y CAGR+53.4%
5y CAGRBook Value
$104.300m
$132.922m
Assets$28.622m
Liabilities$17.882m
DebtDebt to Assets
13.4%
0.9x
Debt to EBITDAFree Cash Flow
-$34.028m
+134.3%
1y CAGR+54.2%
3y CAGR+44.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company